View Clinical Trial (Medical Research Study)

A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis - NCT01096862-35205(Clinical Trial 666945)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Birmingham
State:  
AL
Zip Code: 35205
Conditions: Psoriasis
Purpose: The purpose of this study is to explore the efficacy and safety of multiple, escalating doses of ASP015K when compared to placebo in subjects with moderate to severe plaque psoriasis.
Study summary: Following completion of at least 1 week of study drug for all subjects in group 1, the Sponsor will review the safety information of these subjects prior to enrolling off-treatment subjects into the next dose group. Dose escalation will continue in this manner (unless stopping criteria are met) until all groups have completed the study.
Criteria: Inclusion Criteria: - Subject has moderate to severe plaque psoriasis for 6 months or longer with at least 10% Body Surface Area (BSA) affected - Subject must be a candidate for phototherapy and/or systemic therapy Exclusion Criteria: - Subject has non-plaque psoriasis or drug-induced psoriasis - Subject is on systemic psoriasis therapy within 56 days or 5 half-lives, whichever is longer, prior to first dose of study drug - Subject has a positive TB skin test within 3 months of screening or at screening - Subject has an abnormal chest x-ray
Study is available at:
Birmingham, AL 35205
United States

Primary Contact:
Astellas Pharma Global Development
Email: clintrials.info@us.astellas.com
Phone: 800-888-7704
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.